Distal radius and tibia bone microarchitecture impairment in female patients with diffuse systemic sclerosis
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER LONDON LTD
Citação
OSTEOPOROSIS INTERNATIONAL, v.30, n.8, p.1679-1691, 2019
Resumo
A Summary Radius and tibia bone microarchitecture, analyzed through a high-resolution peripheral quantitative computed tomography, were significantly impaired in female patients with diffuse systemic sclerosis compared with healthy controls. Acroosteolysis, quality of life-grip strength, hand disability, and disease duration were significantly associated with this bone deterioration. Introduction The effect of diffuse systemic sclerosis (dSSc) on the bone is not completely understood. The objective of this study was to analyze the volumetric bone mineral density (vBMD), microarchitecture, and biomechanical parameters at the distal radius and tibia using high-resolution peripheral quantitative computed tomography (HR-pQCT, XtremeCT) in female patients with dSSc and identify clinical and laboratory variables associated with these parameters. Methods Thirty-eight women with dSSc and 76 healthy controls were submitted to HR-pQCT at the distal radius and tibia. Clinical and laboratory findings, bone mineral density(BMD), nailfold capillaroscopy (NC), total passive range of motion(ROM), and quality of life (health assessment questionnaire-HAQ) were associated with HR-pQCT (Scanco Medical AG, Bruttisellen, Switzerland) parameters. Multiple linear regression models adjusted for clinical and laboratory variables, ROM and HAQ, were performed. Results Density, microarchitecture, and biomechanical parameters at the distal radius and tibia were significantly impaired in dSSc patients compared with healthy controls (p < 0.001). Multiple linear regression models showed that lower trabecular density (Tb.vBMD) (radius R-2 = 0.561, p = 0.002; and tibia R-2 = 0.533, p = 0.005), and lower trabecular number (Tb.N) (tibia R-2 = 0.533, p = 0.005) were significantly associated with acroosteolysis. Higher trabecular separation (Tb.Sp) was associated with disease duration and higher HAQ-grip strength (radius R-2 = 0.489, p = 0.013), while cortical density (Ct.vBMD) was associated with ROM (radius R-2 = 0.294, p = 0.002). Conclusion Bone microarchitecture in patients with dSSc, analyzed through HR-pQCT, showed impairment of trabecular and cortical bone at distal radius and tibia. Variables associated with hand involvement (acroosteolysis, quality of life-grip strength, and ROM) and disease duration may be considered prognostic factors of this bone impairment.
Palavras-chave
Acroosteolysis, Grip strength, HR-pQCT, Radius, Range of motion, Systemic sclerosis, Tibia
Referências
- Alvarenga JC, 2017, OSTEOPOROSIS INT, V28, P1335, DOI 10.1007/s00198-016-3876-0
- Arnson Y, 2011, AUTOIMMUN REV, V10, P490, DOI 10.1016/j.autrev.2011.02.002
- Avouac J, 2006, ANN RHEUM DIS, V65, P1088, DOI 10.1136/ard.2005.044602
- Avouac J, 2012, ARTHRIT CARE RES, V64, P1871, DOI 10.1002/acr.21761
- Balint Z, 2014, CLIN EXP RHEUMATOL, V32, pS68
- Cutolo M, 2013, BEST PRACT RES CL RH, V27, P237, DOI 10.1016/j.berh.2013.03.001
- Erre GL, 2008, JOINT BONE SPINE, V75, P426, DOI 10.1016/j.jbspin.2007.07.017
- FERRAZ MB, 1990, J RHEUMATOL, V17, P813
- Fredlani B, 2004, CLIN EXP RHEUMATOL, V22, P313
- Fuller H, 2015, REV BRAS REUMATOL, V55, P352, DOI [10.1016/j.rbr.2014.07.010, 10.1016/j.rbre.2014.07.010]
- Furst DE, 1998, J RHEUMATOL, V25, P84
- Ibn Yacoub Y, 2012, RHEUMATOL INT, V32, P3143, DOI 10.1007/s00296-011-2150-1
- Kilic G, 2016, INT J RHEUM DIS, V19, P405, DOI 10.1111/1756-185X.12242
- Kocijan R, 2014, J BONE MINER RES, V29, P1005, DOI 10.1002/jbmr.2109
- Koutaissoff S, 2011, SEMIN ARTHRITIS RHEU, V40, P455, DOI 10.1016/j.semarthrit.2010.06.008
- Kowal-Bielecka O, 2017, ANN RHEUM DIS, V76, P1327, DOI 10.1136/annrheumdis-2016-209909
- La Montagna G, 2005, SKELETAL RADIOL, V34, P35, DOI 10.1007/s00256-004-0830-6
- Lai CC, 2015, ANN RHEUM DIS, V74, P1347, DOI 10.1136/annrheumdis-2013-204832
- LAMONTAGNA G, 1991, CLIN RHEUMATOL, V10, P18, DOI 10.1007/BF02208027
- LEROY EC, 1988, J RHEUMATOL, V15, P202
- Maddali-Bongi S, 2014, CLIN EXP RHEUMATOL, V32, pS15
- Marot M, 2015, ONCOTARGET, V6, P14865, DOI 10.18632/oncotarget.3806
- Medsger TA, 1999, J RHEUMATOL, V26, P2159
- Medsger TA, 2003, CLIN EXP RHEUMATOL, V21, pS42
- Mok CC, 2013, RHEUMATOLOGY, V52, P296, DOI 10.1093/rheumatology/kes240
- Morardet L, 2016, ARTHRIT CARE RES, V68, P366, DOI 10.1002/acr.22672
- Mugii N, 2006, J RHEUMATOL, V33, P1586
- Omair MA, 2013, J RHEUMATOL, V40, P1881, DOI 10.3899/jrheum.130032
- Park JK, 2016, ARTHRITIS RHEUMATOL, V68, P201, DOI 10.1002/art.39424
- Pistoia W, 2003, BONE, V33, P937, DOI 10.1016/j.bone.2003.06.003
- Poole J L, 1991, Arthritis Care Res, V4, P27, DOI 10.1002/art.1790040106
- Poole JL, 2013, J HAND THER, V26, P232, DOI 10.1016/j.jht.2013.03.002
- Radic M, 2006, CLIN EXP RHEUMATOL, V24, P407
- Sampaio-Barros MM, 2016, REV BRAS REUMATOL, V56, P337, DOI [10.1016/j.rbre.2016.05.006, 10.1016/j.rbr.2016.03.004]
- Sampaio-Barros PD, 2005, CLIN EXP RHEUMATOL, V23, P180
- Sampaio-Barros PD, 2012, J RHEUMATOL, V39, P1971, DOI 10.3899/jrheum.111582
- Sandqvist G, 2009, SCAND J RHEUMATOL, V38, P304, DOI 10.1080/03009740802695466
- Souza RBC, 2006, SCAND J RHEUMATOL, V35, P384, DOI 10.1080/03009740600704296
- Steen VD, 2000, ARTHRITIS RHEUM, V43, P2437, DOI 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U
- Tas DA, 2012, RHEUMATOL INT, V32, P3581, DOI 10.1007/s00296-011-2205-3
- Vilayphiou N, 2016, BONE, V83, P233, DOI 10.1016/j.bone.2015.10.012
- Yuen SY, 2008, J RHEUMATOL, V35, P1073
- Zhu TY, 2015, OSTEOPOROSIS INT, V26, P1759, DOI 10.1007/s00198-015-3077-2
- Zhu TY, 2012, CALCIFIED TISSUE INT, V91, P343, DOI 10.1007/s00223-012-9644-z